Skip to main content
SpringerLink
Log in

Manage psychosis in Parkinson’s disease using a stepwise approach

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Psychosis in Parkinson’s disease arises from complex interactions involving numerous endogenous and exogenous risk factors associated with pathophysiology and can pose a considerable management challenge. The identification of patients at heightened risk of psychosis is important for the prevention and management of this complication. Psychosis in Parkinson’s disease should be treated using a stepwise approach, as psychotic symptoms may be resolved without the addition of specific antipsychotic therapies. Medications available for the specific treatment of psychotic symptoms in Parkinson’s disease, without significantly worsening of motor symptoms, include clozapine, quetiapine, pimavanserin, rivastigmine and donepezil.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(6):629–34.

    Article  PubMed  Google Scholar 

  2. de Lau LML, Verbaan D, van Rooden SM, et al. Relation of clinical subtypes in Parkinson’s disease with survival. Mov Disord. 2014;29(1):150–1.

    Article  PubMed  Google Scholar 

  3. Chang A, Fox SH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76(11):1093–118.

    Article  CAS  PubMed  Google Scholar 

  4. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2008;79(6):652–5.

    Article  CAS  PubMed  Google Scholar 

  5. Janzen J, van ‘t Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol. 2012;259:147–54.

    Article  CAS  PubMed  Google Scholar 

  6. Watanabe H, Senda J, Kato S, et al. Cortical and subcortical brain atrophy in Parkinson’s disease with visual hallucination. Mov Disord. 2013;28(12):1732–6.

    Article  PubMed  Google Scholar 

  7. Fioravanti V, Benuzzi F, Codeluppi L, et al. MRI correlates of Parkinson’s disease progression: a voxel based morphometry study. Parkinsons Dis. 2015;2015:378032.

    PubMed  PubMed Central  Google Scholar 

  8. Fénelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–45.

    Article  PubMed  Google Scholar 

  9. Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson’s disease: a prospective study. Mov Disord. 2007;22(7):938–45.

    Article  PubMed  Google Scholar 

  10. Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858–63.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm. 2004;111(10–11):1447–53.

    Article  CAS  PubMed  Google Scholar 

  12. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.

    Article  PubMed  Google Scholar 

  13. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessement of hallucinations in Parkinson’s disease. Neurology. 2001;57(11):2078–82.

    Article  CAS  PubMed  Google Scholar 

  14. Oeda T, Umemura A, Mori Y, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson’s disease. Neurobiol Aging. 2015;36:3306–13.

    Article  CAS  PubMed  Google Scholar 

  15. Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2006;19:36–40.

    Article  PubMed  Google Scholar 

  16. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1998;21(5):289–95.

    CAS  PubMed  Google Scholar 

  17. Lee JY, Kim JM, Ahn J, et al. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord. 2014;29(1):61–7.

    Article  PubMed  Google Scholar 

  18. Fong TG, Davis D, Growdon ME, et al. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14(8):823–32.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2009;15(4):287–94.

    Article  PubMed  Google Scholar 

  20. Stowe R, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;2:CD006564.

    Google Scholar 

  21. Fénelon G, Soulas T, de Langavant LC, et al. Feeling of presence in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(11):1219–24.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56(Suppl 5):S1–88.

    Article  CAS  PubMed  Google Scholar 

  23. Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother. 2011;12(13):2009–24.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Thomsen TR, Panisset M, Suchowersky O, et al. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008;79(12):1413–5.

    Article  CAS  PubMed  Google Scholar 

  25. Markham Z. Pimavanserin: first global approval. Drugs. 2016;76(10):1053–7.

    Article  CAS  PubMed  Google Scholar 

  26. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.

    Article  CAS  PubMed  Google Scholar 

  27. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002.

    Article  CAS  PubMed  Google Scholar 

  28. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3–7.

    PubMed  Google Scholar 

  29. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171–95.

    Article  CAS  PubMed  Google Scholar 

  30. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25(2):107–10.

    Article  CAS  PubMed  Google Scholar 

  31. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16:184–8.

    Article  PubMed  Google Scholar 

  32. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230–8.

    Article  CAS  PubMed  Google Scholar 

  33. Riederer P, Lange KW, Kornhuber J, et al. Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet. 1991;338:1022–3.

    Article  CAS  PubMed  Google Scholar 

  34. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–63.

    Article  Google Scholar 

  35. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–63.

    Article  PubMed  Google Scholar 

  36. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196–205.

    Article  CAS  PubMed  Google Scholar 

  37. Yasue I, Shinji M, Kishi T, et al. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis. 2016;50:733–40.

    Article  CAS  PubMed  Google Scholar 

  38. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21:1899–907.

    Article  PubMed  Google Scholar 

  39. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Drugs 2016;76(11):1093–118 [3] by salaried employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Manage psychosis in Parkinson’s disease using a stepwise approach. Drugs Ther Perspect 33, 16–21 (2017). https://doi.org/10.1007/s40267-016-0362-x

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0362-x

    Search

    Navigation